Guggenheim Partner's Seamus Fernandez: Oral weight loss pill 'meaningful step up' for Eli Lilly

Eli Lilly's Obesity Drug Data & Regulatory Outlook - Eli Lilly's obesity pill data shows patients with obesity and diabetes lost approximately 105% of their body weight [1] - The new data positions Eli Lilly to seek regulatory approval for its obesity treatment [1] - Guggenheim analyst has a buy rating on Eli Lilly with a price target of $875 [1] Orphoglyon Analysis - Orphoglyon's weight loss results are similar to Wegovy's in diabetic patients [3] - Orphoglyon is viewed as a well-behaved GLP-1 that can be taken orally [3] - The scalability of producing an oral pill is a significant advantage [3] - Eli Lilly's pricing strategy for Orphoglyon is a key unknown factor [4] - Orphoglyon is likely to hit the market in the middle of next year [5] Competitive Landscape - Eli Lilly has a robust pipeline of injectable assets in addition to Orphoglyon [5] - Novo faces challenges in launching new products at the same pace as Eli Lilly [6] - Novo is the number two player in the US GLP-1 market and the number one player globally [6] - The scalability of Novo's oral pill and intellectual property challenges related to compounding are hurdles [7]